ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. Coronary Artery Disease
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1531309
Bioinformatics Analysis of JUP in Patients with Acute Myocardial Infarction and Its Potential Application in Clinical Prognostic Evaluation
Provisionally accepted
- Department of Clinical Laboratory, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background ： Junctional Plakoglobin (JUP) is a critical protein involved in intercellular junctions, playing a significant role in maintaining the structure and function of myocardial cells. However, the expression of JUP in acute myocardial infarction (AMI) and its potential applications in prognostic evaluation of patients remain underexplored. This study aims to investigate the expression levels of JUP in AMI patients and its association with clinical prognosis through bioinformatics analysis.Methods ： A total of 164 patients with acute myocardial infarction admitted from January 2022 to January 2024 were selected as the study subjects. They were divided into an MACE group and a non-MACE group based on the occurrence of adverse prognostic events. Clinical data and myocardial tissue samples from patients post-percutaneous coronary intervention (PCI) were collected. The expression levels of JUP in myocardial tissue were assessed using quantitative real-time PCR (qPCR), and the functional role of the JUP gene in the prognosis of acute myocardial infarction was analyzed. The impact of JUP expression levels on the prognosis of AMI patients was evaluated using Kaplan-Meier method and Cox Proportional Hazards Model.Results： The expression level of JUP in the MACE group was significantly lower than that in the Non-MACE group (P<0.05). The results of the Cox Proportional Hazards Model further indicated that TnI levels (HR=12.512, 95% CI: 1.622-96.507, P<0.05), multi-vessel disease (HR=0.300, 95% CI: 0.108-0.834, P<0.05), and myocardial JUP levels (HR=0.234, 95% CI: 0.065-0.846, P<0.05) were independent predictive factors for post-PCI outcomes in patients with acute myocardial infarction. Kaplan-Meier method revealed a significant association between low JUP expression and adverse prognosis in AMI patients (P<0.05). ROC curve showed that multi-vessel disease (AUC=0.6548, Sensitivity=64.29%, Specificity=66.67%), TnI (AUC=0.8316, Sensitivity=40.71%, Specificity=91.67%), and myocardial JUP (AUC=0.8299, Sensitivity=75.00%, Specificity=84.29%) could all predict the risk of major adverse cardiac events (MACE) after PCI in AMI patients.Conclusion ： The expression level of JUP is decreased in patients with acute myocardial infarction and is closely associated with adverse prognostic outcomes.JUP may serve as a potential biomarker for assessing prognosis in AMI patients, providing new insights for the development of personalized treatment strategies.
Keywords: JUP, AMI, adverse events, prognosis, PG
Received: 20 Nov 2024; Accepted: 18 Apr 2025.
Copyright: © 2025 Deng, Shen and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Leiying Jiang, Department of Clinical Laboratory, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.